Syndax Pharmaceuticals Inc (SNDX) posted $83.3 million in Q3 2026 revenue, driven by strong demand for ReviForge and Niktimvo, while flagging a post-transplant revenue headwind and a CFO transition.
Syndax Pharmaceuticals shows strong Revuforj-driven growth, narrowing losses, and AML upside. Read the latest analysis on SNDX stock here.
Syndax Pharmaceuticals has had a rough run in 2026, and the mixed headlines around its pipeline now put fresh attention on what investors are paying for its current level of sales. The question is whether that recent share price slide still lines up with what the business generates in revenue today. The stock is down about 38.5% year to date, which puts extra weight on the issue of whether today's valuation can still be explained by its sales base. Revuforj winning a major Prix Galien USA...
Why Syndax Pharmaceuticals Stock Is Back in Focus After Q3 Results Syndax Pharmaceuticals (SNDX) moved into the spotlight after reporting third quarter 2026 results, with revenue of US$83.3 million and a net loss of US$49.43 million from continuing operations. The earnings miss and CFO transition have come against a weaker tape, with Syndax Pharmaceuticals’ share price down 25.57% over the past month and 31.34% over 90 days, while the 1 year total shareholder return has declined 4.80%. This...
Find out why Syndax Revuforj is on TIME's list of 2026's best inventions.
SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.
U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencemen
Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.
Syndax Pharmaceuticals, Inc. has an attractive valuation, key readouts in Q4, and an expanding pipeline. Read more on SNDX stock here.
This is the newest page. Registered accounts read further back.